SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

Recent Analyst Ratings for
$OBSV

$OBSV
Press Releases

$OBSV
Analyst Ratings

$OBSV
SEC Filings

$OBSV
Financials

$OBSV
Large Ownership Changes

Chat with this insight

Fastest customizable press release news feed in the world

ObsEva Files Year End 2022 Financial Statements

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ObsEva downgraded by H.C. Wainwright

Cantor Fitzgerald initiated coverage on ObsEva with a new price target

Canaccord Genuity initiated coverage on ObsEva with a new price target

SEC Form 15-12G filed by ObsEva SA

ObsEva SA filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

SEC Form 10-K filed by ObsEva SA

Live finance-specific insights

ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by ObsEva SA

2/11/21 10:27:51 AM ET

$OBSV

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OBSV alert in real time by email

SC 13G/A 1 d18913dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

ObsEva SA

(Name of Issuer)

Common Shares, par value CHF 0.0769 per share

(Title of Class of Securities)

H5861P103

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 2 of 10 Pages

(1)

The percentage of class was calculated based on 55,015,024 shares of the Issuer’s common shares, par value CHF 0.0769 per share (“Common Stock”), as of September 30, 2020, as set forth the Issuer’s Form 6-K, and filed with the Securities and Exchange Commission (the “Commission”) on November 5, 2020.


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 3 of 10 Pages


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 4 of 10 Pages


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 5 of 10 Pages


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 6 of 10 Pages

Item 1.

Issuer


(a)		Name of Issuer:

		ObsEva SA (the “Issuer”)

(b)		Address of Issuer’s Principal Executive Offices:

		Chenin des Aulx, 12 1228 Plan-les-Quates Geneva, Switzerland

Item 2.

Filing Person


(a) – (c)		Name of Persons Filing; Address; Citizenship:

		(i) Medicxi Growth I LP (“Growth I”); (ii) Medicxi Growth Co-Invest I LP (“Growth Co-Invest I”); (iii) Medicxi Growth I GP Limited (“Growth I GP”), which is the sole general partner of Growth I and Growth Co-Invest I; (iv) Medicxi Ventures Management (Jersey) Limited (“Manager”), which is appointed by Growth I GP as the manager of Growth I and Growth Co-Invest I. The address of the principal business office of each of the Reporting Persons is Andrew Jeanne c/o Intertrust Fund Services (Jersey) Limited, 44 Esplanade, St. Helier, Jersey JE4 9WG. Each of Growth I and Growth Co-Invest I is a Jersey limited partnership. Each of Growth I GP and Manager is a Jersey limited liability company.

(d)		Title of Class of Securities:

		Common shares, par value CHF 0.0769 per share

(e)		CUSIP Number: H5861P103

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:



(a)	☐	Broker or dealer registered under Section 15 of the Act;

(b)	☐	Bank as defined in Section 3(a)(6) of the Act;

(c)	☐	Insurance company as defined in Section 3(a)(19) of the Act;

(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940;

(e)	☐	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j)	☐	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

	If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 7 of 10 Pages

Item 4.

Ownership.


(a) and (b)	Amount beneficially owned:

	(i)	Growth I directly owns 1,533,568 shares of Common Stock (the “Growth I Shares”), which represents approximately 2.79% of the outstanding shares of Common Stock.

	(ii)	Growth Co-Invest I directly owns 36,432 shares of Common Stock (the “Growth Co-Invest I Shares”), which represents approximately 0.06% of the outstanding shares of Common Stock.

	(iii)	Growth I GP is the general partner of Growth I and Growth Co-Invest I and may be deemed to beneficially own the Growth I Shares and the Growth Co-Invest I Shares (the “Shares”), which in the aggregate is 1,570,000 shares of Common Stock and represents approximately 2.85% of the outstanding shares of Common Stock.

	(iv)	As Manager has been appointed by Growth I GP as manager of Growth I and Growth Co-Invest I, Manager may be deemed to beneficially own the Shares.

(c)	Number of shares as to which such person has:


	Number of Shares of Common Stock
Reporting Person	(i)		(ii)		(iii)		(iv)
Growth I		1,533,568		0		1,533,568		0
Growth Co-Invest I		36,432		0		36,432		0
Growth I GP		1,570,000		0		1,570,000		0
Manager		1,570,000		0		1,570,000		0

(i)

Sole power to vote or direct the vote

(ii)

Shared power to vote or to direct the vote

(iii)

Sole power to dispose or to direct the disposition of

(iv)

Shared power to dispose or to direct the disposition of

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☒

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 8 of 10 Pages

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 9 of 10 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 11, 2021


Medicxi Growth I LP

By:		/s/ Andrew Jeanne
Name: Andrew Jeanne
Title: Director
For and on behalf of
Medicxi Ventures Management (Jersey) Limited as manager of Medicxi Growth I LP

Medicxi Growth Co-Invest I LP

By:		/s/ Andrew Jeanne
Name: Andrew Jeanne
Title: Director
For and on behalf of
Medicxi Ventures Management (Jersey) Limited as manager of Medicxi Growth Co-Invest I LP

Medicxi Growth I GP Limited

By:		/s/ Andrew Jeanne
Name: Andrew Jeanne
Title: Director

Medicxi Ventures Management (Jersey) Limited

By:		/s/ Andrew Jeanne
Name: Andrew Jeanne
Title: Director


CUSIP No. H5861P103		SCHEDULE 13G/A		Page 10 of 10 Pages

EXHIBIT INDEX


Exhibit

99.1		Joint Filing Statement

Get the next $OBSV alert in real time by email

Date	Price Target	Rating	Analyst
8/30/2022		Buy → Neutral	H.C. Wainwright
6/3/2022	$6.00	Overweight	Cantor Fitzgerald
4/26/2022	$12.00	Buy	Canaccord Genuity
3/28/2022	$12.00	Buy	Aegis Capital
11/29/2021	$17.00 → $15.00	Buy	HC Wainwright & Co.

NAMES OF REPORTING PERSONS

Medicxi Growth I LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Jersey